Identification of KPC-271, a novel KPC variant conferring ceftazidime-avibactam resistance while restoring carbapenem susceptibility in ST15-KL19 Klebsiella pneumoniae

Key Points

• KPC-271 variant restores carbapenem susceptibility while conferring resistance to ceftazidime-avibactam in Klebsiella pneumoniae.
• The study reveals how KPC-271 impacts antibiotic resistance mechanisms and carbapenem-hypersusceptibility.
• Analysis of bacterial strains shows the specific interactions of KPC-271 within the Klebsiella pneumoniae ST15-KL19 lineage.
• These findings highlight the need for continuous monitoring of resistance variants to optimize treatment options.